ACRV

Acrivon TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$3.20

+103.8% vs current

Most likely

Base case

50%

Probability

Target price

$1.45

-7.6% vs current

B-

Bear case

25%

Probability

Target price

$0.75

-52.2% vs current

AI sentiment snapshot

Latest data as of 2026-05-29

AI commentary

Primary-source support is adequate but narrow: the May 13, 2026 SEC filings anchor the thesis to trial timing and runway, but coverage remains limited, no recent trusted-news items were provided, and no usable social context was available. The stock closed at $1.63 on 2026-05-28, and with the deterministic prior still negative across 5d to 120d, this remains a cautious monitoring setup rather than a high-conviction bullish call.

RankAlpha Sentiment Codex - 2026-05-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystPhase 3 readiness remains the next execution checkpoint for ACR-368High impact

Management said ACR-368 is expected to be ready for a Phase 3 confirmatory trial in combination with PD-1 therapy by mid-2026, so the near-term question is execution on timing and regulatory alignment rather than commercialization [#8-K-2026-05-13].

2026-09-15eventSecond-half 2026 simultaneous interim update from the serous endometrial cancer armsHigh impact

The May 13 company update shifted the clearest rerating event to a prespecified simultaneous interim analysis and data update from both biopsy-independent serous endometrial cancer arms of the ACR-368 Phase 2b study in the second half of 2026 [#8-K-2026-05-13].

2027-09-30catalystRunway into the third quarter of 2027 lowers immediate financing stress but not dilution riskHigh impact

Acrivon reported $97.7 million of cash, cash equivalents and investments at March 31, 2026 and said that, together with $7.3 million of subsequent equity-financing proceeds, it expects to fund operations into the third quarter of 2027 [#10-Q-2026-05-13][#8-K-2026-05-13].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-29 • Updated nightlySource: Internal modelMethodology